1型儿茶酚胺敏感性多形性室速的级联筛查影响
本研究纳入82例携带RYR2变异且经父母遗传分析确认来源的CPVT1先证者,分为家族遗传组(n=24)和新发变异组(n=58)。新发变异组变异更多位于C端结构域,且5岁和10岁时首次心脏事件累积发生率高于家族遗传组。级联筛查有助于早期诊断、风险分层和预防性治疗以预防心脏性猝死。
要点
- 新发RYR2变异CPVT1先证者症状发作早于家族遗传者。
- 两组近半数先证者诊断前发生心脏骤停事件。
- 基因阳性同胞至少66.7%有症状,支持级联筛查。
核心结论
- 携带新发RYR2变异的CPVT1先证者较家族遗传者症状发作更早。
- 级联筛查可能有助于早期诊断、风险分层和预防性治疗以预防心脏性猝死。
研究设计与样本
- 纳入82例独立CPVT1先证者(中位年龄10.0(7.0-13.0)岁;45例男性),均携带RYR2变异且经父母遗传分析确认生物学来源。
- 分为确认家族遗传组(n=24)和新发变异组(n=58),检查先证者及携带RYR2变异家属的临床特征。
主要发现
- 新发变异组RYR2变异更多位于C端结构域,较少位于N端结构域。
- 新发变异组先证者5岁和10岁时首次心脏事件(晕厥和心脏骤停或仅心脏骤停)累积发生率高于家族遗传组。
- 两组近半数先证者诊断前经历心脏骤停事件。
- 基因阳性父母仅37.5%有症状,而基因阳性同胞至少66.7%有症状。
临床怎么用
- 对CPVT1先证者应开展级联筛查以识别基因阳性家属。
- 对基因阳性家属进行早期诊断和风险分层,考虑预防性治疗以预防心脏性猝死。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Human cardiac ryanodine receptor 2 (RYR2) shows autosomal-dominant inheritance in catecholaminergic polymorphic ventricular tachycardia type 1 (CPVT1); however, de novo variants have been observed in sporadic cases. Here, we investigated CPVT1-related RYR2 variant inheritance and its clinical significance between familial and de novo cases. METHODS: We enrolled 82 independent CPVT1 probands (median age: 10.0 (7.0-13.0) years; 45 male) carrying the RYR2 variants and whose biological origin could be confirmed by parental genetic analysis: assured familial inheritance (familial group: n=24) and de novo variants (de novo group: n=58). We examined the clinical characteristics of the probands and their family members carrying the RYR2 variants. RESULTS: In the de novo group, the RYR2 variants were more likely located in the C-terminus domain and less likely in the N-terminus domain than those in the familial group. The cumulative incidence of the first cardiac events (syncope and cardiac arrest (CA) or CA only) of the probands at the age of 5 and 10 years was higher in the de novo group than in the familial group. Nearly half of the probands in both groups experienced CA events before diagnosis. Only 37.5% of their genotype-positive parents had symptoms; however, at least 66.7% of the genotype-positive siblings were symptomatic. CONCLUSIONS: CPVT1 probands harbouring de novo RYR2 variants showed an earlier onset of symptoms than those with assured familial inheritance. Cascade screening may enable early diagnosis, risk stratification and prophylactic therapeutic intervention to prevent sudden cardiac death of probands and potential genotype-positive family members.
引用
- Shimamoto K, Ohno S, Kato K, et al. Impact of cascade screening for catecholaminergic polymorphic ventricular tachycardia type 1. Heart. 2022. PMID: 35135837. doi:10.1136/heartjnl-2021-320220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。